Zhang Jie, Li Dan, Huang Xiangning, Long Shanshan, Yu Hua
Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Med (Lausanne). 2022 Feb 15;9:759214. doi: 10.3389/fmed.2022.759214. eCollection 2022.
We aim to analyze the distribution of in different specimen sources and its antibiotic resistance trends from the Antimicrobial Resistant Investigation Network of Sichuan Province (ARINSP) between 2017 and 2020.
According to the monitoring scheme, each participating hospital identified the bacteria and performed antimicrobial susceptibility tests using approved procedures. The data of non-repetitive isolates collected from outpatients and inpatients were submitted to ARINSP. The WHONET 5.6 software was used to analyze the results according to the Clinical and Laboratory Standards Institute (CLSI).
Between 2017 and 2020, 833,408 non-repetitive clinical isolates of bacteria were isolated in total. The bacterial strains isolated from sputum and broncho-alveolar lavage accounted for 48.7, 56.4, 49.2, and 43.7% from 2017 to 2020 respectively, among all sources. The number of isolates from sputum and broncho-alveolar lavage increased from 18,809 in 2018, 19,742 in 2019, to 19,376 in 2020, playing a predominant role among all specimens. Meropenem-resistant occurrences (5.7% in 2017, 7.3% in 2018, 8.0% in 2019, and 7.5% in 2020) remained highest among carbapenems, and increased slightly over time. The resistance rate to tigecycline remained lowest, and declined from 2.4% in 2017, to 0.4% in 2018, and from 0.7% in 2019, to 0.6% in 2020.
The overall resistance rates of to carbapenems increased in Sichuan Province, giving a significant challenge to control related infections. Tigecycline has retained activity to against . Ongoing surveillance is essential. It can help for implementing intervention programs to reduce the occurrence of antimicrobial resistance and to provide with a rational use of antimicrobials.
我们旨在分析2017年至2020年四川省抗菌药物耐药性调查网络（ARINSP）中不同标本来源的[细菌名称未给出]分布情况及其抗生素耐药趋势。
根据监测方案，各参与医院鉴定细菌并使用批准的程序进行抗菌药物敏感性试验。从门诊患者和住院患者中收集的非重复分离株数据提交给ARINSP。使用WHONET 5.6软件根据临床和实验室标准协会（CLSI）分析结果。
2017年至2020年期间，共分离出833,408株非重复临床细菌分离株。在所有来源中，从痰液和支气管肺泡灌洗中分离出的细菌菌株分别占2017年至2020年的48.7%、56.4%、49.2%和43.7%。从痰液和支气管肺泡灌洗中分离出的[细菌名称未给出]菌株数量从2018年的18,809株、2019年的19,742株增加到2020年的19,376株，在所有标本中占主导地位。耐美罗培南的[细菌名称未给出]发生率（2017年为5.7%，2018年为7.3%，2019年为8.0%，2020年为7.5%）在碳青霉烯类药物中仍然最高，且随时间略有增加。对替加环素的耐药率仍然最低，从2017年的2.4%降至2018年的0.4%，从2019年的0.7%降至2020年的0.6%。
四川省[细菌名称未给出]对碳青霉烯类药物的总体耐药率有所上升，给控制[细菌名称未给出]相关感染带来了重大挑战。替加环素对[细菌名称未给出]仍保持活性。持续监测至关重要。它有助于实施干预计划以减少抗菌药物耐药性的发生，并促进抗菌药物的合理使用。
